Egon Pfarr
About
Egon Pfarr is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Cardiology and Cardiovascular Medicine.
According to data from OpenAlex, Egon Pfarr has authored 20 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Endocrinology, Diabetes and Metabolism, 10 papers in Surgery and 6 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Egon Pfarr's work include Diabetes Treatment and Management (15 papers), Pancreatic function and diabetes (8 papers) and Diabetes Management and Research (6 papers). Egon Pfarr is often cited by papers focused on Diabetes Treatment and Management (15 papers), Pancreatic function and diabetes (8 papers) and Diabetes Management and Research (6 papers). Egon Pfarr collaborates with scholars based in Germany, United States and Australia. Egon Pfarr's co-authors include Maximilian von Eynatten, Julio Rosenstock, Jyothis T. George, Darren K. McGuire, Bernard Zinman, Nikolaus Marx, Odd Erik Johansen, Steven E. Kahn, David Baanstra and Thomas Meinicke and has published in prestigious journals such as JAMA, Circulation and Diabetes Care.
In The Last Decade
Egon Pfarr
17 papers receiving 1.8k citations
Hit Papers
Peers
Egon Pfarr
Sven Schnaidt Germany
Mark Warren United States
Thomas Meinicke Germany
Robert Josse Canada
Samuel S. Engel United States
Frans Van de Werf Belgium
John Xie United States
Ira Gantz United States
H.J. Woerle Germany
Maria Gerasimova United States
Citations per year, relative to Egon Pfarr Egon Pfarr (= 1×)
peers
Sven Schnaidt
Countries citing papers authored by Egon Pfarr
Since
Specialization
Citations
This map shows the geographic impact of Egon Pfarr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Egon Pfarr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Egon Pfarr more than expected).
Fields of papers citing papers by Egon Pfarr
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Egon Pfarr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Egon Pfarr. The network helps show where Egon Pfarr may publish in the future.
Co-authorship network of co-authors of Egon Pfarr
This figure shows the co-authorship network connecting the top 25 collaborators of Egon Pfarr. A scholar is included among the top collaborators of Egon Pfarr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Egon Pfarr. Egon Pfarr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Rosenstock, Julio, Ahmed A. Kolkailah, Darren K. McGuire, et al.. (2023). Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial. Diabetes Obesity and Metabolism. 25(6). 1453–1463.
2.
Gandhi, Pranav, et al.. (2021). Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease. BMJ Open Diabetes Research & Care. 9(1). e001313–e001313.
3.
Perkovic, Vlado, Robert D. Toto, Mark E. Cooper, et al.. (2020). Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. Diabetes Care. 43(8). 1803–1812.
4.
Wanner, Christoph, Mark E. Cooper, Odd Erik Johansen, et al.. (2020). Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial. Clinical Kidney Journal. 14(1). 226–236.
5.
McGuire, Darren K., John H. Alexander, Odd Erik Johansen, et al.. (2019). Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Circulation. 139(3). 351–361.
6.
Inagaki, Nobuya, Wenying Yang, Hirotaka Watada, et al.. (2019). Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial. Diabetology International. 11(2). 129–141.
7.
Marx, Nikolaus, Darren K. McGuire, Odd Erik Johansen, et al.. (2019). P6272First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease. European Heart Journal. 40(Supplement_1).
8.
Rosenstock, Julio, Steven E. Kahn, Odd Erik Johansen, et al.. (2019). Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes. JAMA. 322(12). 1155–1155.
9.
Kahn, Steven E., Vlado Perkovic, Odd Erik Johansen, et al.. (2019). SUN-LB015 Baseline Characteristics and Effects on CV and Kidney Outcomes with Linagliptin Versus Placebo, Across GFR Categories in CARMELINA. Journal of the Endocrine Society. 3(Supplement_1).
10.
Balijepalli, Chakrapani, et al.. (2018). PDB12 - CARDIOVASCULAR SAFETY OF EMPAGLIFLOZIN VERSUS GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS: SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISONS. Value in Health. 21. S120–S121.
11.
Balijepalli, Chakrapani, et al.. (2018). Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons. Diabetes Therapy. 9(4). 1491–1500.
12.
Rosenstock, Julio, Vlado Perkovic, John H. Alexander, et al.. (2018). Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. Cardiovascular Diabetology. 17(1). 39–39.
13.
Lee, Joseph H., et al.. (2018). Cost-Effectiveness Analysis of Empagliflozin Compared with Canagliflozin or Standard of Care (SoC) in Patients with T2DM and Established Cardiovascular (CV) Disease. Diabetes. 67(Supplement_1).
14.
Rosenstock, Julio, Vlado Perkovic, Odd Erik Johansen, et al.. (2018). Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk. JAMA. 321(1). 69–69.
15.
Cherney, David Z.I., Søren S. Lund, Bruce A. Perkins, et al.. (2016). The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia. 59(9). 1860–1870.
16.
Diepgen, T. L., Egon Pfarr, & T Zimmermann. (2012). Efficacy and Tolerability of Alitretinoin for Chronic Hand Eczema Under Daily Practice Conditions: Results of the TOCCATA Open Study Comprising 680 Patients. Acta Dermato Venereologica. 92(3). 251–255.
17.
Nakov, Roumen, et al.. (2002). Darusentan: An effective endothelinA receptor antagonist for treatment of hypertension. American Journal of Hypertension. 15(7). 583–589.
18.
Does, R. van der, et al.. (1999). Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris. The American Journal of Cardiology. 83(5). 643–649.
19.
Pfarr, Egon, et al.. (1997). Carvedilol in Comparison and in Combination with Isosorbide Dinitrate Sustained Release in Patients with Chronic Stable Effort-Induced Angina Pectoris. Clinical Drug Investigation. 14(6). 465–473.
20.
Gunawardena, Kulasiri A., et al.. (1997). Carvedilol versus verapamil in chronic stable angina: a multicentre trial. European Journal of Clinical Pharmacology. 52(2). 95–100.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Sven Schnaidt Breakdown of academic impact, for papers by Mark Warren Breakdown of academic impact, for papers by Thomas Meinicke Breakdown of academic impact, for papers by Robert Josse Breakdown of academic impact, for papers by Samuel S. Engel Breakdown of academic impact, for papers by Frans Van de Werf Breakdown of academic impact, for papers by John Xie Breakdown of academic impact, for papers by Ira Gantz Breakdown of academic impact, for papers by H.J. Woerle Breakdown of academic impact, for papers by Maria Gerasimova